Shore Highlights Ongoing Efforts With PARP Inhibitors, Radioligand Therapy in Prostate Cancer

Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies, which he notes are vital for moving the paradigm forward and ultimately improving patient outcomes.

Related Keywords

Myrtle Beach ,South Carolina ,United States , ,Carolina Urologic Research Center ,Neal Shore ,Genesiscare United States ,177lu Psma 617 ,Prostate Cancer ,D ,Pacs ,Nmcrpc ,Radioligand Therapy ,Nmcspc ,Parp Inhibitors ,